BioSpace News Archive

Clinical-stage cannabinoid development company Incannex Healthcare Limited (ASX: IHL) has announced its plans to request an expedited pre-IND meeting for its anti-inflammatory IHL-675 and to pursue an FDA Emergency Use Authorization (EUA) for the treatment of patients suffering from COVID-19.

New Orders and Production Growing; Employment Contracting; Supplier Deliveries Slowing at Faster Rate; Backlog Growing; Raw Materials Inventories Growing; Customers’ Inventories Too Low; Prices Increasing; Exports and Imports Growing

CCT Research, a leader in community-based, embedded clinical research, today announced the expansion of its clinical trial operations to the Salt Lake City metropolitan area.

Combination of free user-friendly web tool, to obtain custom probe sequences, and enzyme-based technology allows for efficient depletion of abundant RNAs for virtually any organism and sample type.

Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced that Merck, known as MSD outside the United States and Canada , has licensed its first TriNKET™ immunotherapy candidate from Dragonf

Aya Healthcare, the digitally driven travel nurse staffing and healthcare workforce solutions company that’s transformed the healthcare staffing industry across the United States , was selected by Modern Healthcare and its judges as an award winner in the 2020 Healthcare Marketing Impact Awards. Aya’s Nurses Week Video Campaign was

Company’s first specialty drug is therapeutically equivalent to Firazyr ® and is a cost-effective generic alternative to currently marketed products for the treatment of acute attacks of hereditary angioedema Fresenius Kabi launches KabiCare patient support program in U.S. to promote access to essential medications

The preclinical research demonstrates that combining the oncolytic virus CF33 with an immune checkpoint inhibitor results in lasting resistance to certain tumors

EVerZom’s ambition is to transform regenerative medicine and the field of biotherapies thanks to these «super» biological nanoparticles, the exosomes.

Rhizen announces the approval of its IND by USFDA for its oral DHODH inhibitor for SARS-CoV-2 infection and plans to initiate a first-in-man single ascending dose study in healthy volunteers in early December. Initial study to be potentially followed by a multiple-ascending dose study in Covid-19 patients, in line with pre-IND discussions with the FDA. RP7214 is potentially a best-in-class, selective, DHODH inhibitor with potent SARS-CoV-2